Home › NDC Lookup › RxCUI directory › RxCUI 1745438

Glycerin 200 MG/ML / lidocaine 50 MG/ML / phenylephrine hydrochloride 2.5 MG/ML Medicated... — RxCUI 1745438

RxNorm drug concept · Semantic clinical drug
RxCUI 1745438 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1745438
Official nameGlycerin 200 MG/ML / lidocaine 50 MG/ML / phenylephrine hydrochloride 2.5 MG/ML Medicated Pad
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asglycerin 20 % / lidocaine 5 % / phenylephrine hydrochloride 0.25 % Medicated Pad; glycerin 20 % / lidocaine 5 % / phenylephrine HCl 0.25 % Medicated Pad
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lidocaine Transdermal Patch: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It relieves nerve pain from post-herpetic neuralgia, the lingering pain that can follow shingles. It is used in adults. It numbs the pain signals in the skin under the patch.
  • Usually up to 12 hours in a 24-hour period, then 12 hours off. Put it on intact skin over the most painful spot. Do not use more patches than prescribed.
  • No. Heat can increase how much lidocaine gets absorbed. With Ztlido, you can apply a patch after brief heat, but never put a heating pad or electric blanket directly on it.
  • For Ztlido, light exercise and short water exposure, like a 10-minute shower, are okay. Gently pat it dry rather than rubbing. If the edges lift, press them down.
📖 Read our full Lidocaine Transdermal Patch guide →

🕸️ Concept Web — How Glycerin 200 MG/ML / lidocaine 50 MG/ML / phenyl... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Glycerin 200 MG/ML / lidocaine 50 MG/ML / phenylephrine hydrochloride 2.5 MG/ML Medicated Pad RxCUI 1745438

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Glycerin 4910
    • Lidocaine 6387
    • Phenylephrine 8163
    • Glycerin / lidocaine / phenylephrine 1745437
    • Phenylephrine hydrochloride 8164
  2. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Glycerin / lidocaine / phenylephrine Medicated Pad 1745436
    • Glycerin / lidocaine / phenylephrine hydrochloride Medicated Pad 2649356
    • Glycerin / lidocaine / phenylephrine Medicated Pad or Tape 1745434
    • Glycerin / lidocaine / phenylephrine Topical Product 1745435
    • Glycerin / lidocaine / phenylephrine hydrochloride Medicated Pad or Tape 2663589
    • Glycerin / lidocaine / phenylephrine hydrochloride Topical Product 2659703
    • Medicated Pad 797271
    • Medicated Pad or Tape 1151124
    • +1 more in this family
  3. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Glycerin 200 MG/ML 345106
    • Lidocaine 50 MG/ML 329928
    • Phenylephrine hydrochloride 2.5 MG/ML 997282

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Glycerin 200 MG/ML SCDC · 345106
  • Lidocaine 50 MG/ML SCDC · 329928
  • Phenylephrine hydrochloride 2.5 MG/ML SCDC · 997282
  • Glycerin / lidocaine / phenylephrine Medicated Pad SCDF · 1745436
  • Glycerin / lidocaine / phenylephrine hydrochloride Medicated Pad SCDFP · 2649356
  • Glycerin / lidocaine / phenylephrine Medicated Pad or Tape SCDG · 1745434
  • Glycerin / lidocaine / phenylephrine Topical Product SCDG · 1745435
  • Glycerin / lidocaine / phenylephrine hydrochloride Medicated Pad or Tape SCDGP · 2663589
  • Glycerin / lidocaine / phenylephrine hydrochloride Topical Product SCDGP · 2659703

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1745438 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00573-0554-20 20 POUCH in 1 CARTON (0573-0554-20) / 1 CLOTH in 1 POUCH Preparation H Rapid Relief Haleon US Holdings LLC 2019-03-01
Observed labelers: Haleon US Holdings LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.